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digestive toxicities in 10 (17%) pts. There was a trend of lower severe 
esophagitis when amifostine was administered. 
Of the 56 pts evaluable for response, 13 achieved a complete response 
(CR=23%), 24 achieved a partial response (PR= 43%) for an overall 
RR of 66% (95%CI: 54-78%). 15 pts had stable disease (SD=27%), 
and 4 pts had progressive disease (PD= 7%). RR was signifﬁcanly 
higher when at least 4 cycles of chemotherapy have been given, 
75.68% vs 38.9% ( p= 0.01).
Progression - free survival curve showed at 1, 2, and 3- years, rates of 
39%, 19% and 7%, (95% CI:3-18%) with a median time to progression 
of 10.3 months.
The 1, 2 and 3- year disease speciﬁc S rates were 61%, 33% and 21%, 
(95% CI:12-34%), with the median S of 17.3 months. For the 11 pa-
tients still alive the median follow-up was 37.5 months. All evaluations 
were done considering α =0.05.
Conclusions: Concurrent chemoradiotherapy with Vinorelbine and 
a Platinum compound followed by consolidation ChT with the same 
drugs given for advanced stage III NSCLC is feasible, well tolerated 
and has a positive effect on the RR and S.
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Study Objecitives: Large cell neuroendocrine carcinoma of the lung 
(LCNEC) are considered poor prognosis. This study was undertaken 
to evaluate the efﬁcacy of perioperative adjuvant chemotherapy in 
patients with radically resected with LCNEC. 
Design: Retrospective study.
Patients: Thirty-two (3.2 %) of 1,007 patients with primary lung 
carcinoma who underwent tumor resection from 1999 to 2005 at Tokyo 
Medical Universtiy were found to have tumors with the histological 
characteristics of LCNEC were enrolled as subjects of this study. 
Results: The median age of the patients was 65 years (range, 40-83 
years). Twenty-ﬁve (78%) patients were male, and 7 (22%) were fe-
male. Twenty-two (92%) of 24 were present or past smokers. Operative 
procedures performed included 28 lobectomies (88%), 2 partial resec-
tions (6%), and 2 pneumonectomies (6%). The distribution of patho-
logical stage was 9 (28%) in stage IA, 10 (31%) in stage IB, 3 (10%) 
in stage IIA, 2 (6%) in stage IIB, 6 (19%) in stage IIIA, and 2(6%) in 
stage IIIB. Thirteen (41%) of 32 patients were received perioperative 
chemotherapy including 4 induction chemotherapies and 9 adjuvant 
chemotherapies. Of these, 11 (85%) patients had taken platinum-based 
chemotherapy before or after surgery. The 2-year actuarial overall 
survival for the entire group was 79.0% (55% of 2-year survival at 
Asamura H. et al JCO 2006) (Figure 1a). Survival for patients with 
perioperative adjuvant chemotherapy was higher than that with surgery 
alone (P=0.18) (Figure 1b). The 2-year survival rate of patients with 
perioperative adjuvant chemotherapy was 85.7%, whereas 74.5% of 
patients with surgery alone.
Conclusions: In this series, we think perioperative adjuvant chemo-
therapy including platinum-based regimen for LCNEC might improve 
survival. Further study such as a prospective clinical trial is mostly 
needed. 
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Background: We performed a prospective phase II study to determine 
the efﬁcacy of induction chemoradiotherapy (chemo-RT) followed 
surgery in locally advanced non-small-cell lung cancer (LA-NSCLC). 
Methods: Eightheen patients (pts) were included between January 05 
to August 06 (14 men, 5 women, median age of 57 years). A majority of 
pts had a histology of SCC (n: 14) and stage IIIA (n: 13). Patients with 
KPS d70 and technically resectable T1-4, N2, M0 NSCLC were treated 
induction chemo-RT (45 Gy RT + cisplatin 60 mg/m2 and docetaxel 60 
mg/m2) on days 1 and 22 and were reassessed after induction chemo-
RT. A surgical resection was performed within median 5 weeks. Two 
additional cycles of chemotherapy were given after surgery. In those 
with unresectable disease, two cycles were administrated during deﬁni-
tive RT with 63 Gy. Postoperative RT was given to pts according to 
pathological prognostic factors. 
Results: After the induction treatment, 66% (12/18) of pts achieved a 
partial response. The main acute toxicities were hematologic toxicity 
and esophagitis. Ten pts underwent surgery and resectability rate was 
55% (10/18). Operative morbidity and mortality were not seen. Patho-
logical downstaging and complete response were obtained in 9 (50%) 
and 6 (33%) pts, respectively. Postoperative RT (1440-1800 cGy) was 
delivered in 17% (n:3) of the pts.
Median follow-up time was 11 months at time to evaluation (January 
2007). During the follow-up time, distant metastasis was developed of 
7 pts and 3 pts died. Mean overall and progression-free survival times 
were 18,7 (1-24 months) and 17,5 months (1-20 months), respectively. 
Conclusion: Response and resection rates were achieved by 66%, 
50% in our study. This treatment method was found to be feasible and 
promising.
